Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 7/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | AGXT | P21549 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3079998 | 0.72 | TSHR (0.48) | CYP2D6IDO1KMT2AAGXTTSHR | |
| SCHEMBL3276722 | 0.72 | TSHR (0.52) | CYP2D6IDO1KMT2AAGXTTSHR | |
| SCHEMBL12191546 | 0.71 | TSHR (0.46) | CYP2D6IDO1KMT2AAGXTTSHR | |
| SCHEMBL12085925 | 0.70 | TSHR (0.38) | CYP2D6IDO1KMT2AAGXTTSHR | |
| SCHEMBL12162627 | 0.69 | TSHR (0.44) | CYP2D6IDO1KMT2AAGXTTSHR | |
| SCHEMBL16326323 | 0.69 | TSHR (0.44) | CYP2D6IDO1KMT2AAGXTTSHR | |
| SCHEMBL11911980 | 0.69 | TSHR (0.44) | CYP2D6IDO1KMT2AAGXTTSHR | |
| SCHEMBL2640220 | 0.69 | TSHR (0.44) | CYP2D6IDO1KMT2AAGXTTSHR | |
| SCHEMBL2874130 | 0.69 | TSHR (0.44) | CYP2D6IDO1KMT2AAGXTTSHR | |
| SCHEMBL2644673 | 0.69 | TSHR (0.48) | CYP2D6IDO1KMT2AAGXTHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779008-B2 | Polymeric micelles for drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130195987-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8263665-B2 | Polymeric micelles for drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8258190-B2 | Encapsulated contrast agents | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8066824-B2 | Covalent modification of metal surfaces | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-7799339-B2 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20100159020-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100136063-A1 | Immunotherapy for Treatment of Amyloid-Related Disorders Using Encapsulated Beta-Amyloid Peptides | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-06-03 | — | — | US | disclosed |
| US-7638558-B2 | drug loaded micelle of a triblock polymer tert-butylphenylsilylpropene-polyethylene glycol-b-poly(tert-butylaspartic acid-b-polyphenylalanine-copoly( tert-buyltyrosine) has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7618944-B2 | Encapsulating in micelle which is a block copolymer containing hydrophilic and hydrophobic blocks | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7601796-B2 | polyamideether copolymer has a hydrophilic polyethylene glycol and a hydrophobic polyamino acid blocks; modified polyethylene glycol homopolymer; forming conjugate polymer drug; resin peptides; use in pharmaceutically acceptable compositions | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090092554-A1 | ENCAPSULATED CONTRAST AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20080274173-A1 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080274965-A1 | ENCAPSULATED AMYLOID-BETA PEPTIDES | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080035243-A1 | Covalent modification of metal surfaces | INTEZYNE TECHNOLOGIES (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136063-A1 | Immunotherapy for Treatment of Amyloid-Related Disorders Using Encapsulated Beta-Amyloid Peptides | IAPP, APP, TTR | ADRB2 2577/4885ADRB1 2254/4885ADRB3 1983/4885 |
| US-20080035243-A1 | Covalent modification of metal surfaces | ITGAL, ITGA1, ITGA5 | ADRB2 4777/4885ADRB1 4771/4885ADRB3 4518/4885 |
| US-20080274965-A1 | ENCAPSULATED AMYLOID-BETA PEPTIDES | IAPP, APP, TTR | ADRB2 2047/4885ADRB1 1686/4885ADRB3 1386/4885 |
| US-20130195987-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | ABCB4, CLTB, CD47 | ADRB2 2586/4885ADRB1 1264/4885ADRB3 1501/4885 |
| US-20090092554-A1 | ENCAPSULATED CONTRAST AGENTS | LIPA, LPXN, CD47 | ADRB2 2274/4885ADRB1 2437/4885ADRB3 1527/4885 |
| US-20080274173-A1 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | CLTB, SLC1A5, CLTA | ADRB2 2772/4885ADRB1 2444/4885ADRB3 3198/4885 |
| US-20100159020-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | ABCB4, CLTB, CD47 | ADRB2 2586/4885ADRB1 1264/4885ADRB3 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.